Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Colon Cancer
ELOXATIN approved for colon cancer treatment following surgery
December 12th, 2004
Sanofi-Synthelabo, a member of the sanofi-aventis Group, announced that the U.S. Food and Drug Administration (FDA) has approved ELOXATIN, in combination with conventional chemotherapy (infusional 5-fluorouracil/leucovorin, known as 5-FU/LV), for the adjuvant (postsurgical) treatment of patients with Stage III colon cancer who have undergone complete resection of the primary tumor. This is the first new chemotherapy approval for the adjuvant treatment of colon cancer in over a decade, offering patients new hope for potential cure of this disease, one of the nation's deadliest forms of cancer. "The FDA approval of ELOXATIN in this setting provides...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
